



Study	I ²	Odds Ratio (95% CrI)
-------	----------------	----------------------


Placebo vs Afatinib




Gefitinib vs Almonertinib




Lazertinib vs Amivantamab_Lazertinib




Osimertinib vs Amivantamab_Lazertinib



Erlotinib vs Chemotherapy



0.03 1 30



Study	I ²	Odds Ratio (95% CrI)
-------	----------------	----------------------

Erlotinib vs DHFRi

r18		0.96 (0.10, 9.1)
Pooled (pair-wise)		0.94 (0.0014, 7.4e+02)
Indirect (back-calculated)		NA
Pooled (network)		0.99 (0.025, 37.)

antiangio vs Erlotinib_antiangio

37		5.0e+25 (6.5e-27, 3.9e+77)
Pooled (pair-wise)		1.3e+22 (2.7e-24, 4.3e+68)
Indirect (back-calculated)		11. (0.53, 2.3e+02)
Pooled (network)	0.0%	12. (1.1, 4.7e+02)

Erlotinib_chemotherapy vs Erlotinib

67		2.7 (0.15, 50.)
71		4.6e+17 (9.6e-24, 2.2e+58)
Pooled (pair-wise)	0.0%	3.0 (0.0065, 5.0e+03)
Indirect (back-calculated)		NA
Pooled (network)	0.0%	3.0 (0.19, 74.)

Erlotinib_HER3i vs Erlotinib

62		1.2 (0.17, 8.0)
Pooled (pair-wise)		1.1 (0.0019, 7.8e+02)
Indirect (back-calculated)		NA
Pooled (network)		1.1 (0.040, 41.)

Erlotinib_IGF_1Ri vs Erlotinib

44		0.99 (0.17, 5.8)
9		2.2e+12 (2.4e-07, 2.0e+31)
Pooled (pair-wise)	56.3%	2.2 (0.084, 6.0e+03)
Indirect (back-calculated)		NA
Pooled (network)	54.1%	2.0 (0.17, 63.)

